QI
SLDB icon

QS Investors’s Solid Biosciences SLDB Stock Holding History

QS Investors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$279K Buy
+5,080
New +$336K ﹤0.01% 963

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

QS Investors's SLDB Position: Q2 2021 in Review

QS Investors opened a new position in Solid Biosciences (SLDB) in Q2 2021: 5,080 shares worth $279K. The stake represents ﹤0.01% of the portfolio and ranks #963 among its holdings.

92 funds tracked by Wall St. Rank hold SLDB as of Q2 2021.

  • QS Investors held 5,080 shares of Solid Biosciences worth $279K as of Q2 2021.
  • Solid Biosciences was a new QS Investors position in Q2 2021.
  • Solid Biosciences made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #963 holding.
  • 92 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.